Sociodemographic and clinical characteristics of study participants
| Characteristic . | Entire cohort (N = 416) . | Self-report phenotype . | |||||
|---|---|---|---|---|---|---|---|
| Perfect reporter (n = 50)* . | Overreporter (n = 98)† . | P‡ . | |||||
| No. . | % . | No. . | % . | No. . | % . | ||
| Median age at study participation, y (range) | 6 (2-20) | 6 (2-19) | 7 (2-20) | .0311 | |||
| Sex | .49 | ||||||
| Male | 277 | 66.6 | 35 | 70 | 63 | 64.3 | |
| Female | 139 | 33.4 | 15 | 30 | 35 | 35.7 | |
| Race/ethnicity | .014 | ||||||
| Non-Hispanic white | 148 | 35.6 | 19 | 38 | 18 | 18.4 | |
| Hispanic | 154 | 37.0 | 19 | 38 | 42 | 42.9 | |
| Asian | 56 | 13.5 | 8 | 16 | 13 | 13.3 | |
| African American | 58 | 13.9 | 4 | 8 | 25 | 25.5 | |
| Annual household income, $K | .48 | ||||||
| <50 | 238 | 60.6 | 29 | 59.2 | 65 | 69.1 | |
| 50-100 | 96 | 24.4 | 11 | 22.4 | 15 | 16.0 | |
| >100 | 59 | 15.0 | 9 | 18.4 | 14 | 14.9 | |
| Maternal education less than college degree | 231 | 57.2 | 27 | 54.0 | 58 | 61.0 | .41 |
| Paternal education less than college degree | 242 | 60.9 | 29 | 59.2 | 68 | 73.1 | .09 |
| NCI risk group19 | .23 | ||||||
| Standard | 255 | 61.6 | 32 | 64 | 52 | 53.6 | |
| High | 159 | 38.4 | 18 | 36 | 45 | 46.4 | |
| Median 6MP dose intensity (range)§ | 0.86 (0.06-2.97) | 0.87 (0.06-1.2) | 0.91 (0.17-2.97) | .066 | |||
| TPMT WT genotype | 389 | 93.5 | 47 | 94 | 91 | 92.9 | .79 |
| Median TGN levels (pmol/8 × 108 erythrocytes) (range) | 147.3 (0.26-714.1) | 157.2 (39.3-714.1) | 136.3 (0.26-607.6) | .0062 | |||
| 6MP adherence|| | |||||||
| Mean adherence rate | 0.91 | 0.99 | 0.76 | <.001 | |||
| Nonadherers | 165 | 39.7 | 0 | 0.0 | 77 | 78.6 | <.001 |
| Characteristic . | Entire cohort (N = 416) . | Self-report phenotype . | |||||
|---|---|---|---|---|---|---|---|
| Perfect reporter (n = 50)* . | Overreporter (n = 98)† . | P‡ . | |||||
| No. . | % . | No. . | % . | No. . | % . | ||
| Median age at study participation, y (range) | 6 (2-20) | 6 (2-19) | 7 (2-20) | .0311 | |||
| Sex | .49 | ||||||
| Male | 277 | 66.6 | 35 | 70 | 63 | 64.3 | |
| Female | 139 | 33.4 | 15 | 30 | 35 | 35.7 | |
| Race/ethnicity | .014 | ||||||
| Non-Hispanic white | 148 | 35.6 | 19 | 38 | 18 | 18.4 | |
| Hispanic | 154 | 37.0 | 19 | 38 | 42 | 42.9 | |
| Asian | 56 | 13.5 | 8 | 16 | 13 | 13.3 | |
| African American | 58 | 13.9 | 4 | 8 | 25 | 25.5 | |
| Annual household income, $K | .48 | ||||||
| <50 | 238 | 60.6 | 29 | 59.2 | 65 | 69.1 | |
| 50-100 | 96 | 24.4 | 11 | 22.4 | 15 | 16.0 | |
| >100 | 59 | 15.0 | 9 | 18.4 | 14 | 14.9 | |
| Maternal education less than college degree | 231 | 57.2 | 27 | 54.0 | 58 | 61.0 | .41 |
| Paternal education less than college degree | 242 | 60.9 | 29 | 59.2 | 68 | 73.1 | .09 |
| NCI risk group19 | .23 | ||||||
| Standard | 255 | 61.6 | 32 | 64 | 52 | 53.6 | |
| High | 159 | 38.4 | 18 | 36 | 45 | 46.4 | |
| Median 6MP dose intensity (range)§ | 0.86 (0.06-2.97) | 0.87 (0.06-1.2) | 0.91 (0.17-2.97) | .066 | |||
| TPMT WT genotype | 389 | 93.5 | 47 | 94 | 91 | 92.9 | .79 |
| Median TGN levels (pmol/8 × 108 erythrocytes) (range) | 147.3 (0.26-714.1) | 157.2 (39.3-714.1) | 136.3 (0.26-607.6) | .0062 | |||
| 6MP adherence|| | |||||||
| Mean adherence rate | 0.91 | 0.99 | 0.76 | <.001 | |||
| Nonadherers | 165 | 39.7 | 0 | 0.0 | 77 | 78.6 | <.001 |
Statistics were calculated by excluding patients with missing values for characteristics.
Perfect reporters had no difference between self-report and MEMS for all study months.
Overreporters had a self-report that exceeded their MEMS report by ≥5 days in ≥50% of study months.
P value for comparison of overreporters with perfect reporters.
6MP dose intensity is the ratio of 6MP dose actually prescribed (mg/m2 body surface area) to the planned protocol dose (75 mg/m2/d).
6MP adherence rate is the ratio of number of days with MEMS cap openings (X) to number of days 6MP was prescribed (N), reported as a percentage (X/N × 100). 6MP nonadherence is the MEMs-based adherence rate of <95%.